Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations

On the heels of announcing a restructuring plan that reduces its workforce by 30%, Black Diamond Therapeutics (Nasdaq:BDTX) has announced that its discovery engine was featured in the peer-reviewed Cancer Research journal.

The journal is published by American Association for Cancer Research (AACR).

A paper highlighted in the journal explained how the company’s Mutation-Allostery-Pharmacology (MAP) discovery engine identified and experimentally validated 22 new oncogenic HER2 driver mutations.

The paper is titled “Computational and Functional Analyses of HER2 Mutations Revealing Allosteric Activation Mechanisms and Altered Pharmacologic Effects.”

The analysis highlights work from researchers at Black Diamond Therapeutics and Foundation Medicine (Cambridge, Massachusetts), who used the MAP discovery engine to produce a list of 222 known and potential driver mutations from 820 single-nucleotide variants.

The scientists screened 111 using Ba/F3…

Read more
  • 0

Black Diamond Therapeutics doses first patient in Phase 1 study focused on non-small cell lung cancer NSCLC and glioblastoma

Black Diamond Therapeutics (Nasdaq: BDTX) has announced that it has dosed the first patient in the Phase 1 study focused on BDTX-1535.

BDTX-1535 is a MasterKey inhibitor of epidermal growth factor receptor (EGFR) to potentially treat non-small cell lung cancer (NSCLC) and glioblastoma (GBM).

Cambridge, Massachusetts–based Black Diamond believes BDTX-1535 holds significant potential for EGFR-mutant NSCLC and GBM.

“This is the second MasterKey inhibitor derived from our MAP drug discovery engine; we are incredibly excited about BDTX-1535’s advancement into the clinic, and we look forward to providing a clinical update in the second half of 2023,” said David M. Epstein, CEO of Black Diamond Therapeutics.

“Despite recent successes in targeting EGFR-mutated NSCLC, there is still a need for better therapeutics for patients with disease progression following first-line EGFR inhibitors,” said Dr. Melissa Johnson, director of lung cancer research for Sara…

Read more
  • 0